[A20-83] Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2020
Commission awarded on 01.09.2020 by the Federal Joint Committee (G-BA).
Airways and respiratory system
|Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene with a minimal function mutation|
|Exclusively positive effects in comparison with BSC; hint of major added benefit|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.